Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.

Sridhar ChilimuriHaozhe SunAhmed AlemamKyoung-Sil KangPeter LaoNikhitha MantriLawrence SchillerMyroslava SharabunElona ShehiJairo TejadaAlla YugaySuresh Kumar Nayudu

Published in: Journal of clinical pharmacy and therapeutics (2020)

Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
juvenile idiopathic arthritis
high intensity
early onset
rheumatoid arthritis patients
respiratory syndrome coronavirus
drug induced
systemic lupus erythematosus